The US FDA Acts To Bolster Adverse Event Reporting For Compounded Drugs

 
• By Joanne S. Eglovitch

After discovering one firm suppressed over 4,000 compounded-hormone adverse event reports, agency leans on compounders and outsourcers to improve reporting.

Clipboard with medical form and sign Hormone Replacement Therapy. - Image
FDA Wants Drug Compounding Pharmacies To Up Their Adverse Reporting Game • Source: Shutterstock

More from Manufacturing

More from Compliance